| Project/Area Number |
24390326
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Nakajima Jun 東京大学, 医学部附属病院, 教授 (90188954)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAKIMI Kazuhiro 東京大学, 医学部附属病院, 特任教授 (80273358)
MURAKAWA Tomohiro 東京大学, 医学部附属病院, 登録研究員 (50359626)
MATSUSHITA Hirokazu 東京大学, 医学部附属病院, 特任講師 (80597782)
SANO Atsushi 東京大学, 医学部附属病院, 登録診療員 (20569834)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
|
|---|
| Keywords | 胸膜中皮腫 / 細胞移入治療 / γδT細胞 / メソテリン / ＣＡＲ / NOGマウス / 細胞傷害活性 / 抗腫瘍効果 / αβT細胞 / メソテリン特異的受容体 / NOGマウス、抗腫瘍効果 / 免疫細胞治療 / CAR / メッセンジャーRNA / エレクトロポレーション(EP)法 / ACC-Meso4 / Chimeric Antigen Receptor(CAR) / メッセンジャーRNA(mRNA) |
|---|
| Outline of Final Research Achievements |
To develop antigen-specific immunotherapy for malignant mesothelioma, we established mesothelin-specific chimeric antigen receptor (MesoCAR) inducedγδTcells. MesoCAR mRNA was transduced into γδTcells, and optimal conditions of MesoCAR+γδTcell adoptive therapy for in vivo and in vitro mesothelioma models were investigated. Anti-tumor effects of MesoCAR+γδTcells were observed, and the anti-tumor effects were comparable to or might be better than those of MesoCAR+ αβTcells. Off-tumor/on-target toxicity to normal tissues was not seen, and the graft-versus host disease was not induced. MesoCAR+ γδTcell adoptive therapy may be an effective treatment without causing major side-effects for mesothelioma or other mesothelin-positive tumors.
|
